NCT05498597View on ClinicalTrials.gov

AMT-151 in Patients With Selected Advanced Solid Tumours

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 25, 2023

Primary Completion Date

January 1, 2024

Study Completion Date

October 30, 2024

Conditions
Advanced Solid TumorAdvanced CancerAdvanced CarcinomaOvarian CancerOvarian CarcinomaOvarian Epithelial CancerOvarian Endometrioid AdenocarcinomaEndometrial CancerEndometrial AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Clear Cell AdenocarcinomaLung AdenocarcinomaTriple Negative Breast CancerPancreatic Ductal AdenocarcinomaMalignant Pleural MesotheliomaOvarian Clear Cell CarcinomaOvarian Clear Cell AdenocarcinomaOvarian Mucinous Adenocarcinoma
Interventions
DRUG

AMT-151

Administered intravenously

Trial Locations (9)

200032

NOT_YET_RECRUITING

Shanghai Tumor Hospital, Shanghai

350014

NOT_YET_RECRUITING

Fujian Provincial Cancer Hospital, Fuzhou

410031

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

Unknown

RECRUITING

Chris O'Brien Lifehouse, Sydney

RECRUITING

ICON Cancer Centre, Brisbane

RECRUITING

Mater Cancer Care Centre, South Brisbane

RECRUITING

Cancer Research SA, Adelaide

RECRUITING

Cabrini Malvern Hospital, Malvern

RECRUITING

One Clinical Research (OCR), Perth

Sponsors
All Listed Sponsors
collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

lead

Multitude Therapeutics Inc.

INDUSTRY